Skip to main content
SpringerLink
Log in

Bronchopulmonary Dysplasia/Chronic Lung Disease

  • Chapter
Neonatology

Abstract

Bronchopulmonary dysplasia (BPD) is the most common cause of chronic lung disease in infancy [1]. The consensus definition of BPD has been summarized in Table 65.1. The “classic” BPD described by Northway in 1967 has now been replaced by less severe forms of “new” BPD, which are infrequently found in patients >30 weeks of gestation and with birth weights (BW) >1200 grams. Presently, infants who weigh <1250 grams account for 97% of all BPD patients [2]. The incidence of BPD, defined as oxygen need at 36 weeks post-menstrual age (PMA), was 52% (BW 501–750 g), 34% (BW 751–1000 g), 15% (BW 1001–1200g), and 7% (BW 1201–1500 g). Using a physiologic definition based on an oxygen reduction challenge at 36 weeks PMA led to a 10% decrease in the incidence of BPD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baraldi E, Filippone M (2007) Chronic lung disease after premature birth. N Engl J Med 357: 1946–1955

    Article  PubMed  CAS  Google Scholar 

  2. Walsh MC, Szefler S, Davis J et al (2006) Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117: S52–S56

    PubMed  Google Scholar 

  3. Coalson JJ (2006) Pathology of bronchopulmonary dysplasia. Semin Perinatol 30: 179–184

    Article  PubMed  Google Scholar 

  4. Bhandari V, Bizzarro MJ, Shetty A et al (2006) Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 117: 1901–1906

    Article  PubMed  Google Scholar 

  5. Lavoie PM, Pham C, Jang KL (2008) Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics 122: 479–485

    Article  PubMed  Google Scholar 

  6. Bokodi G, Treszl A, Kovacs L et al (2007) Dysplasia: a review. Pediatr Pulmonol 42: 952–961

    Article  PubMed  Google Scholar 

  7. Bhandari V, Gruen JR (2006) The genetics of bronchopulmonary dysplasia. Semin Perinatol 30: 185–191

    Article  PubMed  Google Scholar 

  8. Van Marter LJ, Dammann O, Allred EN et al (2002) Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 140: 171–176

    Article  PubMed  Google Scholar 

  9. Bhandari V, Elias JA (2006) Cytokines in tolerance to hyperoxiainduced injury in the developing and adult lung. Free Radic Biol Med 41: 4–18

    Article  PubMed  CAS  Google Scholar 

  10. Bhandari A, Bhandari V (2003) Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci 8: e370–e380

    Article  PubMed  CAS  Google Scholar 

  11. Bhandari A, Bhandari V (2007) Bronchopulmonary dysplasia: an update. Indian J Pediatr 74: 73–77

    Article  PubMed  Google Scholar 

  12. Speer CP (2006) Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 11: 354–362

    Article  PubMed  Google Scholar 

  13. Ryan RM, Ahmed Q, Lakshminrusimha S (2008) Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia. Clin Rev Allergy Immunol 34: 174–190

    Article  PubMed  CAS  Google Scholar 

  14. Thomson A, Bhandari V (2008) Pulmonary biomarkers of bronchopulmonary dysplasia. Biomark Insights 3: 361–373

    Google Scholar 

  15. Bhandari V, Choo-Wing R, Lee CG et al (2006) Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 12: 1286–1293

    Article  PubMed  CAS  Google Scholar 

  16. Aghai ZH, Faqiri S, Saslow JG et al (2007) Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: attenuation by dexamethasone. J Perinatol 28: 149–155

    Article  PubMed  Google Scholar 

  17. Baier RJ, Majid A, Parupia H et al (2004) CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia. Pediatr Pulmonol 37: 137–148

    Article  PubMed  Google Scholar 

  18. Kevill K, Bhandari V, Kettuman M et al (2008) A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol 180: 601–608

    PubMed  CAS  Google Scholar 

  19. Cederqvist K, Sorsa T, Tervahartiala T et al (2001) Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics 108: 686–692

    Article  PubMed  CAS  Google Scholar 

  20. Rehan V, Torday J (2006) Lower parathyroid hormone related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. Pediatr Res 60: 216–220

    Article  PubMed  CAS  Google Scholar 

  21. Niu JO, Munshi U, Siddiq M et al (1998) Early increase in endothelin-1 in tracheal aspirates of preterm infants:correlation with bronchopulmonary dysplasia. J Pediatr 132: 965–970

    Article  PubMed  CAS  Google Scholar 

  22. Ambalavanan N, Novak ZE (2003) Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates. Pediatr Res 53: 240–244

    Article  PubMed  CAS  Google Scholar 

  23. Thebaud B, Abman S (2007) Bronchopulmonary dysplasia- where have all the vessels gone? Role of angiogenic growth factors inchronic lung disease. Am J Respir Crit Care Med 175: 978–985

    Article  PubMed  CAS  Google Scholar 

  24. Bhandari V, Choo-Wing R, Lee CG et al (2008) Developmental regulation of NO-mediated VEGF-induced effects in the lung. Am J Respir Cell Mol Biol 39: 420–430

    Article  PubMed  CAS  Google Scholar 

  25. Ekekezie, II, Thibeault DW, Simon SD et al (2004) Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. Pediatrics 113: 1709–1714

    Article  PubMed  Google Scholar 

  26. Vento G, Capoluongo E, Matassa PG et al (2006) Serum levels of seven cytokines in premature, ventilated newborns, correlation with old and new forms of bronchopulmonary dysplasia. Intensive Care Med 32: 723–730

    Article  PubMed  CAS  Google Scholar 

  27. Cullen A, Van Marter LJ, Allred EN et al (2002) Urine bombesinlike peptide elevation precedes clinical evidence of bronchopulmonary dysplasia. Am J Respir Crit Care Med 165: 1093–1097

    PubMed  Google Scholar 

  28. Bland RD, Xu L, Ertsey R et al (2007) Dysregulation of pulmonary elastin synthesis and assembly in preterm lambs with chronic lung disease. Am J Physiol Lung Cell Mol Physiol 292: L1370–1384

    Article  PubMed  CAS  Google Scholar 

  29. Hirakawa H, Pierce RA, Bingol-Karakoc G et al (2007) Cathepsin S deficiency confers protection from neonatal hyperoxia-induced lung injury. Am J Respir Crit Care Med 176: 778–785

    Article  PubMed  CAS  Google Scholar 

  30. Padela S, Cabacungan J, Shek S et al (2005) Hepatocyte growth factor is required for alveologenesis in the neonatal rat. Am J Respir Crit Care Med 172: 907–914

    Article  PubMed  Google Scholar 

  31. Frank L (2003) Protective effect of keratinocyte growth factor against lung abnormalities associated with hyperoxia in prematurely born rats. Biol Neonate 83: 263–272

    Article  PubMed  CAS  Google Scholar 

  32. Bry K, Whitsett JA, Lappalainen U (2007) IL-1beta disrupts postnatal lung morphogenesis in the mouse. Am J Respir Cell Mol Biol 36: 32–42

    Article  PubMed  CAS  Google Scholar 

  33. Choo-Wing R, Nedrelow JH, Homer RJ et al (2007) Developmental differences in the responses of IL-6 and IL-13 transgenic mice exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol 293: L142–L150

    Article  PubMed  CAS  Google Scholar 

  34. Vozzelli MA, Mason SN, Whorton MH et al (2004) Antimacrophage chemokine treatment prevents neutrophil and macrophage influx in hyperoxia-exposed newborn rat lung. Am J Physiol Lung Cell Mol Physiol 286: L488–L493

    Article  PubMed  CAS  Google Scholar 

  35. Vicencio AG, Lee CG, Cho SJ et al (2004) Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia? Am J Respir Cell Mol Biol 31: 650–656

    Article  PubMed  CAS  Google Scholar 

  36. Thebaud B, Ladha F, Michelakis ED et al (2005) Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 112: 2477–2486

    Article  PubMed  CAS  Google Scholar 

  37. Subramaniam M, Bausch C, Twomey A et al (2007) Bombesin-like peptides modulate alveolarization and angiogenesis in bronchopulmonary dysplasia. Am J Respir Crit Care Med 176: 902–912

    Article  PubMed  CAS  Google Scholar 

  38. Agrons A, Courtney S, Stocker J et al (2005) From the archives of the AFIP: Lung disease in premature neonates: radiologic-pathologic correlation. Radiographics 25: 1047–1073

    Article  PubMed  Google Scholar 

  39. Bhandari A, Panitch HB (2006) Pulmonary outcomes in bronchopulmonary dysplasia. Semin Perinatol 30: 219–226

    Article  PubMed  Google Scholar 

  40. Doyle LW, Faber B, Callanan C et al (2006) Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 118: 108–113

    Article  PubMed  Google Scholar 

  41. Hofhuis W, Huysman MW, van der Wiel EC et al (2002) Worsening of V′maxFRC in infants with chronic lung disease in the first year of life: a more favorable outcome after high-frequency oscillation ventilation. Am J Respir Crit Care Med 166: 1539–1543

    Article  PubMed  Google Scholar 

  42. Short EJ, Kirchner HL, Asaad GR et al (2007) Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med 161: 1082–1087

    Article  PubMed  Google Scholar 

  43. Anderson PJ, Doyle LW (2006) Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol 30: 227–232

    Article  PubMed  Google Scholar 

  44. Ehrenkranz RA, Walsh MC, Vohr BR et al (2005) Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116: 1353–1360

    Article  PubMed  Google Scholar 

  45. Jeng SF, Hsu CH, Tsao PN et al (2008) Bronchopulmonary dysplasia predicts adverse developmental and clinical outcomes in verylow-birthweight infants. Dev Med Child Neurol 50: 51–57

    Article  PubMed  Google Scholar 

  46. Watterberg KL, Gerdes JS, Cole CH et al (2004) Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114: 1649–1657

    Article  PubMed  Google Scholar 

  47. Howlett A, Ohlsson A (2003) Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev:CD000366

    Google Scholar 

  48. Stevens TP, Harrington EW, Blennow M et al (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 3:CD003063

    Google Scholar 

  49. Morley CJ, Davis PG, Doyle LW et al (2008) Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 358: 700–708

    Article  PubMed  CAS  Google Scholar 

  50. Bhandari V, Gavino RG, Nedrelow JH et al (2007) A randomized controlled trial of synchronized nasal intermittent positive pressure ventilation in RDS. J Perinatol 27: 697–703

    Article  PubMed  CAS  Google Scholar 

  51. Kugelman A, Feferkorn I, Riskin A et al (2007) Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study. J Pediatr 150: 521–526

    Article  PubMed  Google Scholar 

  52. Barrington KJ, Finer NN (2007) Inhaled nitric oxide for preterm infants: a systematic review. Pediatrics 120: 1088–1099

    Article  PubMed  Google Scholar 

  53. Davis JM, Parad RB, Michele T et al (2003) Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 111: 469–476

    Article  PubMed  Google Scholar 

  54. Pfister RH, Soll RF, Wiswell T (2007) Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 4:CD006069

    Google Scholar 

  55. Bell EF, Acarregui MJ (2008) Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 1:CD000503

    Google Scholar 

  56. Bhandari A, Bhandari V (2009) Pitfalls, problems and progress in bronchopulmonary dysplasia. Pediatrics 123: 1562–1573

    Article  PubMed  Google Scholar 

  57. Greenough A (2007) How has research in the past 5 years changed my clinical practice. Arch Dis Child Fetal Neonatal Ed 92: F404–F407

    Article  PubMed  Google Scholar 

  58. Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD001456

    Google Scholar 

  59. Kamlin CO, Davis PG (2004) Long versus short inspiratory times in neonates receiving mechanical ventilation. Cochrane Database Syst Rev 4:CD004503

    Google Scholar 

  60. Ambalavanan N, Carlo WA (2006) Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 30: 192–199

    Article  PubMed  Google Scholar 

  61. Bhandari V (2006) Non-invasive ventilation of the sick neonate: evidence-based recommendations. J Neonat 20: 214–221

    Google Scholar 

  62. Miller JD, Carlo WA (2007) Safety and effectiveness of permissive hypercapnia in the preterm infant. Curr Opin Pediatr 19: 142–144

    Article  PubMed  Google Scholar 

  63. Henderson-Smart DJ, Davis PG (2003) Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev 1:CD000139

    Google Scholar 

  64. Schmidt B, Roberts RS, Davis P et al (2006) Caffeine therapy for apnea of prematurity. N Engl J Med 354: 2112–2121

    Article  PubMed  CAS  Google Scholar 

  65. Tyson JE, Wright LL, Oh W et al (1999) Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 340: 1962–1968

    Article  PubMed  CAS  Google Scholar 

  66. Darlow BA, Graham PJ (2007) Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 4:CD000501

    Google Scholar 

  67. Bhandari V, Brodsky N, Porat R (2005) Improved outcome of extremely low birth weight infants with Tegaderm application to skin. J Perinatol 25: 276–281

    Article  PubMed  Google Scholar 

  68. Oh W, Poindexter BB, Perritt R et al (2005) Association between Fluid Intake and Weight Loss during the First Ten Days of Life and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants. J Pediatr 147: 786–790

    Article  PubMed  Google Scholar 

  69. Lai NM, Rajadurai SV, Tan KH (2006) Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/chronic lung disease. Cochrane Database Syst Rev 3:CD005093

    Google Scholar 

  70. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Delayed (JO THERESA3weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 1:CD001145

    Google Scholar 

  71. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1:CD001144

    Google Scholar 

  72. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1:CD001146

    Google Scholar 

  73. Baveja R, Christou H (2006) Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 30: 209–218

    Article  PubMed  Google Scholar 

  74. Khemani E, McElhinney DB, Rhein L et al (2007) Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 120: 1260–1269

    Article  PubMed  Google Scholar 

  75. Bhandari A, Schramm CM, Kimble C et al (2008) Effect of a short course of prednisolone in infants with oxygen-dependent bronchopulmonary dysplasia. Pediatrics 121: e344–e349

    Article  PubMed  Google Scholar 

  76. Ng GY, da S, Ohlsson A (2001) Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 3:CD003214

    Google Scholar 

  77. Brundage KL, Mohsini KG, Froese AB et al (1990) Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis 142: 1137–1142

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, USA

    Vineet Bhandari

Authors
  1. Vineet Bhandari
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Obstetrics and Reproductive Medicine, Division of Neonatology, University of Siena General Hospital S. Maria alle Scotte Azienda Ospedaliera Universitaria Senese, Siena, Italy

    Giuseppe Buonocore (Professor of Pediatrics and Neonatology, Head of School of Pediatrics) (Professor of Pediatrics and Neonatology, Head of School of Pediatrics)

  2. University of Siena, Siena, Italy

    Rodolfo Bracci (Formerly Professor of Pediatrics and Head of Department of Pediatrics, Obstetrics and Reproductive Medicine) (Formerly Professor of Pediatrics and Head of Department of Pediatrics, Obstetrics and Reproductive Medicine)

  3. University of Liverpool, UK

    Michael Weindling (Professor of Perinatal Medicine, Director of Postgraduate Research, Head of School of Paediatrics Mersey Deanery) (Professor of Perinatal Medicine, Director of Postgraduate Research, Head of School of Paediatrics Mersey Deanery)

  4. Department of Women’s and Children’s Health, Institute of Translational Medicine, Liverpool, UK

    Michael Weindling (Professor of Perinatal Medicine, Director of Postgraduate Research, Head of School of Paediatrics Mersey Deanery) (Professor of Perinatal Medicine, Director of Postgraduate Research, Head of School of Paediatrics Mersey Deanery)

  5. Liverpool Women’s Hospital, Liverpool, UK

    Michael Weindling (Professor of Perinatal Medicine, Director of Postgraduate Research, Head of School of Paediatrics Mersey Deanery) (Professor of Perinatal Medicine, Director of Postgraduate Research, Head of School of Paediatrics Mersey Deanery)

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Italia

About this chapter

Cite this chapter

Bhandari, V. (2012). Bronchopulmonary Dysplasia/Chronic Lung Disease. In: Buonocore, G., Bracci, R., Weindling, M. (eds) Neonatology. Springer, Milano. https://doi.org/10.1007/978-88-470-1405-3_65

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1405-3_65

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1404-6

  • Online ISBN: 978-88-470-1405-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation